Created at	Source	Raw Value	Validated value
Dec. 4, 2022, 8 p.m.	usa	Average Days in COVID-19 Symptoms by Type of Therapy in the UMF 20 and UMF 13 of the IMSS.;Crosstabulated Outcome in Modification of the Evolution Clinical vs Fails Therapeutic by Type of Treatment in Patients With COVID-19 UMF 13 and UMF 20 of the IMSS	Average Days in COVID-19 Symptoms by Type of Therapy in the UMF 20 and UMF 13 of the IMSS.;Crosstabulated Outcome in Modification of the Evolution Clinical vs Fails Therapeutic by Type of Treatment in Patients With COVID-19 UMF 13 and UMF 20 of the IMSS
Nov. 20, 2022, noon	usa	None	None
Aug. 17, 2021, 6 p.m.	usa	Average Days in COVID-19 Symptoms by Type of Therapy in the UMF 20 and UMF 13 of the IMSS.;Crosstabulated Outcome in Modification of the Evolution Clinical vs Fails Therapeutic by Type of Treatment in Patients With COVID-19 UMF 13 and UMF 20 of the IMSS	Average Days in COVID-19 Symptoms by Type of Therapy in the UMF 20 and UMF 13 of the IMSS.;Crosstabulated Outcome in Modification of the Evolution Clinical vs Fails Therapeutic by Type of Treatment in Patients With COVID-19 UMF 13 and UMF 20 of the IMSS
Dec. 19, 2020, 12:31 a.m.	usa	Estimate clinical symptoms by days of follow-up in patients with COVID-19 under treatment with Azithromycin/Ivermectin/Ribaroxaban/Paracetamol vs. Azithromycin/Ribaroxaban/Paracetamol followed by video call for 14 days from U.M.F 13 and U.M.F 20	Estimate clinical symptoms by days of follow-up in patients with COVID-19 under treatment with Azithromycin/Ivermectin/Ribaroxaban/Paracetamol vs. Azithromycin/Ribaroxaban/Paracetamol followed by video call for 14 days from U.M.F 13 and U.M.F 20